Search results for

On this broadcast of The National Conversation, we'll answer your questions about treatment and traveling in the future. We'll also hear from some people who have recovered from the disease.

Severe cases of COVID-19 can injure the brain in ways that affect memory, thinking and mood for months after the infection is gone, new research hints. It may even raise the risk of Alzheimer's.

NPR's Michel Martin speaks with Ruth Faden, founder of the Berman Institute of Bioethics at Johns Hopkins University, about the ethics of determining who gets vaccinated when resources are limited.

Bipartisan negotiators are trying to finalize a coronavirus deal with money for businesses, jobless Americans and vaccine distribution. The top Republican says they should vote on items they agree on.

Even when forced online by the pandemic, music therapy sessions continue to help patients in some ways talk therapy can't. "Music is this portal," says one therapist and COVID-19 long-hauler.

The medical supply chain is in crisis. Governors and experts are putting growing pressure on the White House to take a much bigger supply role instead of nudging states and industry to step up.

At least 11 cases of the viral disease are linked to a British man's ski trip to the Alps after attending a conference in Singapore.

Updated on May 1, 2020 at 12pm Athersys, a biotechnology company in Cleveland, has been developing a possible therapy for serious medical conditions such as acute respiratory distress syndrome (ARDS) – one of the more concerning complications caused by COVID-19. The company announced in a press release on Friday May 1, 2020, that University Hospitals is starting a clinical trial testing the effectiveness of this treatment on patients with COVID-19 induced ARDS.

New studies strongly support the use of corticosteroids to treat COVID-19. These drugs are inexpensive and widely available. Early controversy over their effectiveness may now largely be settled.

COVID-19 continues to sweep its way across the country.